Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation
NCT05509933Phase 3Recruiting
- Sponsor
- Henry Ford Health
- Start
- Nov 2022
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of budesonide in Engraftment syndrome (ES), sponsored by Henry Ford Health. Started Nov 2022; status: recruiting.
02
Drugs
budesonide
03
Conditions
Engraftment syndrome (ES)
Beyond the preview
Go deeper on NCT05509933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05509933.